Fig. 5

Spreading of immune response to other TAA. a. Number of TAA-specific responses in the TG4010 arm with patient classified per the diversity of MUC1-specific response (LD^MUC1 (n = 16) vs HD^MUC1 (n = 31)). Dots are representative of individual patients; the horizontal bar represents the average number of response b. Same as in A for patients of the placebo arm (LD^MUC1 (n = 9) vs HD^MUC1 (n = 22)). c Number of TAA-specific responses in the TG4010 arm with patients classified per the acquisition or not of MUC1-specific responses during treatment (Subjects with unchanged baseline MUC1 response without change upon treatment (n = 28) vs. Subjects with acquisition of a de novo response (n = 16)). d: Same as in C for patients of the placebo arm (Subjects with unchanged baseline MUC1 response without change upon treatment (n = 20) vs. Subjects with acquisition of a de novo response (n = 11)). (*: p < 0.05, **: p < 0.01, ns: not significant, non parametric Mann-Whitney test)